Macquarie Group Ltd. trimmed its holdings in Celgene Co. (NASDAQ:CELG) by 6.1% in the third quarter, Holdings Channel reports. The institutional investor owned 2,062,246 shares of the biopharmaceutical company’s stock after selling 132,872 shares during the quarter. Macquarie Group Ltd.’s holdings in Celgene were worth $300,717,000 at the end of the most recent reporting period.
Several other institutional investors have also added to or reduced their stakes in CELG. Thompson Davis & CO. Inc. increased its position in Celgene by 5.9% in the second quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after purchasing an additional 43 shares during the period. Arcadia Investment Management Corp MI increased its position in Celgene by 118.7% in the third quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 400 shares during the period. Guidant Wealth Advisors acquired a new stake in Celgene in the third quarter worth about $119,000. Motco increased its position in Celgene by 19.3% in the second quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock worth $127,000 after purchasing an additional 159 shares during the period. Finally, Penserra Capital Management LLC acquired a new stake in Celgene in the second quarter worth about $129,000. 79.85% of the stock is owned by institutional investors and hedge funds.
Celgene Co. (NASDAQ:CELG) opened at $104.82 on Wednesday. Celgene Co. has a 1-year low of $94.55 and a 1-year high of $147.17. The company has a current ratio of 3.65, a quick ratio of 3.52 and a debt-to-equity ratio of 1.31. The firm has a market capitalization of $82,530.00, a PE ratio of 24.72, a PEG ratio of 0.68 and a beta of 1.77.
A number of analysts recently commented on CELG shares. Morgan Stanley lowered Celgene from an “equal weight” rating to an “underweight” rating and set a $120.00 price objective for the company. in a research report on Thursday, October 5th. Sanford C. Bernstein lowered Celgene from an “outperform” rating to a “market perform” rating and set a $121.00 price objective for the company. in a research report on Wednesday, December 27th. BTIG Research reiterated a “hold” rating on shares of Celgene in a research report on Sunday, October 22nd. Cantor Fitzgerald reiterated a “hold” rating and issued a $112.00 price objective on shares of Celgene in a research report on Monday, October 30th. Finally, Vetr upgraded Celgene from a “buy” rating to a “strong-buy” rating and set a $144.39 price objective for the company in a research report on Monday, October 23rd. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and nineteen have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $131.18.
ILLEGAL ACTIVITY NOTICE: This report was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://sportsperspectives.com/2018/01/17/celgene-co-celg-shares-sold-by-macquarie-group-ltd.html.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.